GENOMICS
Comprising a Purification System (below) and Integrated Sequencer (right), the Ion Torrent Genexus System is a two-instrument NGS platform that automates the main steps in the NGS workflow.
immediate. TAT for test results went from three weeks to 24 hours or less. The cost per test also decreased by about 30%. These improvements directly address a bottleneck in precision medicine: delays in test results. Research has shown that delays in biomarker test results prevent nearly half of advanced NSCLC patients (over 38,000 in one study2
) from
accessing precision oncology. Another study confirmed that initiating the correct therapy from the outset is critical, as even later switches to tailored treatments may not fully compensate for initial delays.3 By eliminating the wait time associated with outsourcing, we’re accelerating genomic testing, making it easier to drive research forward and expand targeted therapy options. Bringing NGS testing in-house has completely changed how we approach molecular diagnostics and proved that even smaller community hospitals can successfully adopt this technology. Beyond cutting turnaround times and costs, this shift also helps identify more patients for clinical trials; which is key to advancing molecular
research and shaping the future of precision medicine. Plans are already in place to expand the tumor types we test for, including a myeloid panel, and we’re growing our team with the addition of a hematopathologist to support this. As we continue expanding our capabilities, our hope is that our experience inspires other healthcare organizations to embrace these new precision medicine solutions. There’s growing evidence supporting genomic sequencing and we believe solutions like in-house NGS are the answer to providing timely, effective treatments.
Genexus system The Ion Torrent Genexus System (Thermo Fisher Scientific) is a two-instrument NGS platform that automates the main steps in the NGS workflow, including sample purification and quantification, library preparation, sequencing, bioinformatics analysis, and reporting. The Genexus Purification
System and Genexus Integrated
Beyond cutting turnaround times and costs, this shift also helps identify more patients for clinical trials – which is key to advancing molecular research and shaping the future of precision medicine
WWW.PATHOLOGYINPRACTICE.COM JUNE 2025
Sequencer work together seamlessly with Genexus software, tracking sample information and results automatically through the process. This automated system reduces manual steps and facilitates quality data and quick reports, making in-house NGS testing accessible to more researchers regardless of experience and without the requirement to hire or train additional staff. The system makes NGS workflows fast and easy with walkaway automation, so laboratories of all experience levels are able to access the benefits of in-house NGS. These advancements to the NGS workflow provide operational efficiency by reducing hands-on time and staff required for NGS testing, freeing up valuable time to focus on other priorities or to scale up the testing done in the laboratory. The Genexus System also increases reproducibility of NGS assays and provides long-term cost savings due to decreased labour requirements and combined service and support options by using multiple instruments from the same trusted partner.
In the first step of this automated NGS
workflow, the Purification System quickly extracts and quantifies nucleic acids with hands-free automation, eliminating manual pipetting steps from sample preparation. Next, the Integrated Sequencer automates library prep, templating, sequencing, data analysis and reporting, delivering true end-to-end automated NGS workflow.
45
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
